title: [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
abstract: In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives. In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI). In ACS it is recommended to start therapy with clopidogrel with 300 mg loading dose with subsequent transition to maintenance dose 75 mg/day. Preliminary therapy with clopidogrel (in combination with ASA) before emergent or elective PCI significantly decreases risk of development of unfavorable clinical outcomes. In PCI loading dose of clopidogrel is 300-600 mg while duration of maintenance therapy (75 mg/day) depends on the type of used coronary stent. After implantation of bare stent duration of therapy with clopidogrel should be not less than 1 month (ideally no less that 12 months) and after implantation of drug-eluting stent - not less than 12 months.
authors.forename: D V
authors.initials: DV
authors.lastname: Preobrazhenskiĭ
authors.forename: B A
authors.initials: BA
authors.lastname: Sidorenko
authors.forename: T A
authors.initials: TA
authors.lastname: Batyraliev
authors.forename: A
authors.initials: A
authors.lastname: Vural
authors.forename: M
authors.initials: M
authors.lastname: Islek
authors.forename: O
authors.initials: O
authors.lastname: Avsar
authors.forename: D V
authors.initials: DV
authors.lastname: Fettser
mesh_terms: D054058:Acute Coronary Syndrome / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D000572:American Heart Association; D000800:Angioplasty, Balloon / Q000009:adverse effects*; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin